Abstract:The prevalence of persistent pulmonary hypertension of newborn (PPHN) has been estimated 1.9/1000 live births. Although the efficacy of inhaled nitric oxide and extracorporeal membrane oxygenation in PPHN is well established but it is difficult to administer and monitor in resource limited countries. Owing to this, other treatment options need to be evaluated.This is a prospective observational study conducted in the Pediatric Cardiology Department, NICVD, Karachi, from February 2020 to October 2020 after the approval from the Institutional Ethical Review Committee. All the neonates referred to our Unit were screened by echocardiography (echo) and those who fulfilled the inclusion criteria were included. Echo were done before starting sildenafil and after 72 h to assess the pressure gradient across tricuspid valve and right to left or bidirectional shunt across patent ductus arteriosus , patent foramen ovale , or both. Sildenafil was started with a dose of 1 mg/kg/dose thrice a day and increased to 2 mg/kg/dose after 48 h if partial pressure of oxygen (PO<a href="#">1</a> Thérèse P. Persistent pulmonary hypertension of the newborn. Paediatr Respir Rev. 2006;7:175–176.<a href="/servlet/linkout?suffix=CIT0001&dbid=16&doi=10.1080%2F14767058.2021.1923003&key=10.1016%2Fj.prrv.2006.04.211">[Crossref]</a>, <a href="/servlet/linkout?suffix=CIT0001&dbid=8&doi=10.1080%2F14767058.2021.1923003&key=16938639">[PubMed]</a> , <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=175-176&author=P.+Th%C3%A9r%C3%A8se&title=Persistent+pulmonary+hypertension+of+the+newborn">[Google Scholar]</a>] did not increase. In neonates who did not respond to increased dose of Sildenafil were added on oral Bosentan 1 mg/kg/dose twice a day.Total 82 newborns were enrolled. Fifty-two patients improved after 48 h so were continued on same treatment. Sildenafil dose was increased in 30 (37.9%) patients whose PO2 did not increase to at least 10% from baseline after 48 h of starting treatment. Three patients expired within 48–72 h. Out of 27 remaining patients, only four responded whereas 23 patients did not show any improvement. In these patients, Bosentan was supplemented along with sildenafil.The results of our study show effectiveness of oral Sildenafil in treating PPHN. The overall improvement observed in the patients was overwhelming. Combination of Sildenafil with Bosentan is beneficial in patients who did not respond on Sildenafil alone.

Successful treatment of persistent pulmonary hypertension of the newborn with bosentan

Effect of bosentan therapy in persistent pulmonary hypertension of the newborn

The Progress in the Treatment of Persistent Pulmonary Hypertension in Neonatal

Bosentan in the treatment of persistent pulmonary hypertension in newborns: a systematic review and meta-analysis

Effectiveness of Bosentan VS Sildenafil for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial

Oral drugs used to treat persistent pulmonary hypertension of the newborn

Comparison of the Effectiveness of Bosentan and Sildenafil in the Management of Persistent Pulmonary Arterial Hypertension in Neonates

Efficacy, safety and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in persistant pulmonary hypertension of newborn (PPHN)

Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial

Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial

Persistent Pulmonary Hypertension of the Newborn: The Efficacy Comparison of Vasodilators Sildenafil Plus Bosentan Versus Sildenafil Plus Beraprost at a Tertiary Childcare Health Facility

Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital

Persistent pulmonary hypertension of the newborn: therapeutical approach.

Progression of periodontal disease in adult subjects in the absence of periodontal therapy.

Comparison of Efficacy between Sildenafil Alone and Sildenafil with Milrinone for Treatment of Persistent Pulmonary Hypertension of the Newborn

Persistent Pulmonary Hypertension of the Newborn: Recent Advances in the Management

Current and Future Treatments for Persistent Pulmonary Hypertension in the Newborn

Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn

Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches